© 2020 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Multiple Myeloma
FDA Grants Priority Review to Ide-Cel for Relapsed/Refractory Multiple Myeloma
September 22, 2020
The FDA granted a Priority Review designation to idecabtagene vicleucel as treatment of adult patients with multiple myeloma who have received at least 3 prior therapies, including an immunomodulatory drug, a proteasome inhibitor, and an anti-CD38 antibody.
Expert Discusses the BOSTON Trial of Selinexor in Multiple Myeloma
September 11, 2020
Noopur S. Raje, MD, discusses the results of the BOSTON trial of selinexor, bortezomib, and dexamethasone in patients with multiple myeloma.
Ixazomib Combination Shows 13+ Month PFS in Multiple Myeloma
September 10, 2020
The efficacy of ixazomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone plus placebo was shown in the phase 3 TOURMALINE-MM2 trial for patients with newly diagnosed multiple myeloma who were not eligible for autologous stem cell transplant, according to a press release from Takeda.
Daratumumab Leads to Deep Responses Among Newly Diagnosed Black Patients With Multiple Myeloma
September 10, 2020
Adding the anti-CD38 antibody, daratumumab, to the standard of care regimen of lenalidomide, bortezomib, and dexamethasone, improved depth of response, stringent complete response , and minimal residual disease negativity, in a subgroup of Black patients who had newly diagnosed multiple myeloma, according to findings presented at the eighth annual Society of Hematologic Oncology meeting.
CLR 131 Continues to Show Encouraging Responses in Triple Refractory Multiple Myeloma
September 09, 2020
CLR 131 induced a clinically meaningful objective response rate of 40% as treatment of patients with multiple myeloma who are triple class refractory in the phase 2 CLOVER-1 clinical trial.
FDA Grants Priority Review to Melflufen for Triple-Class Refractory Multiple Myeloma
August 31, 2020
The FDA granted Priority Review to Melphalan flufenamide in combination with dexamethasone for the treatment of adult patients with multiple myeloma that is refractory to a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.
Ganguly Details Treatments for Standard-Risk Multiple Myeloma
August 28, 2020
Siddhartha Ganguly, MD, reviewed the case of a 51-year-old man with standard-risk multiple myeloma.
Gasparetto Addresses Triplet Versus Doublet Induction Options in Multiple Myeloma
August 21, 2020
During a virtual Case Based Peer Perspective event, Cristina Gasparetto, MD, discussed the case of a geriatric male diagnosed with stage II multiple myeloma.
FDA Approves Daratumumab Plus Kd Regimen in Relapsed/Refractory Multiple Myeloma
August 20, 2020
The FDA granted approval to the combination of daratumumab plus carfilzomib and dexamethasone as treatment of adult patients with relapsed or refractory multiple myeloma who have received up to 3 prior lines of therapy.
Berdeja Compares Later-Line Therapies in Multiple Myeloma
August 17, 2020
As part of a virtual Case Based Peer Perspective event, Jesus G. Berdeja, MC, discussed the treatment options for stage II multilple myeloma, based on a case of a 71-year female patient.